NCT04389632 2026-04-20
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen Inc.
Phase 1 Recruiting
Clinical Trials
45 trialsNCT07219212 2026-04-13
LUMIRAY
Johnson & Johnson Enterprise Innovation Inc.
Phase 1 Recruiting
NCT02819752 2026-04-09
PEACH
Royal Marsden NHS Foundation Trust
Phase 1 Terminated
NCT06236425 2026-04-01
TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
NCT04722523 2026-03-30
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT07435311 2026-02-27
A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
R-Pharm
Phase 1 Completed
NCT02567422 2025-12-04
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02495896 2025-11-10
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
University of Southern California
Phase 1 Active not recruiting
NCT02381535 2025-02-11
Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin
National Cancer Institute (NCI)
Phase 1 Completed
NCT03509012 2025-01-14
CLOVER
AstraZeneca
Phase 1 Completed
NCT02113878 2024-11-05
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
Dana-Farber Cancer Institute
Phase 1 Completed
NCT03028766 2024-09-19
WISTERIA
University of Birmingham
Phase 1 Completed
NCT02308072 2024-05-08
ORCA-2
University College, London
Phase 1 Active not recruiting
NCT04892875 2023-11-30
PANTHEoN
Vanderbilt-Ingram Cancer Center
Phase 1 Withdrawn
NCT02158234 2023-01-19
Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02764593 2022-11-29
Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer
RTOG Foundation, Inc.
Phase 1 Completed
NCT02775812 2022-06-10
Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT04947241 2021-07-01
Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase 1 Unknown
NCT02585973 2021-06-29
Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT02537223 2021-04-19
Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer
University Health Network, Toronto
Phase 1 Completed
NCT02658214 2020-08-20
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Phase 1 Completed
NCT04361409 2020-04-28
Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
China Medical University Hospital
Phase 1 Completed
NCT00006036 2020-04-06
Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors
Canadian Cancer Trials Group
Phase 1 Completed
NCT01064921 2019-06-04
Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02508246 2019-03-13
WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck
University of Washington
Phase 1 Completed
NCT02433626 2019-02-01
COTI2-101
Critical Outcome Technologies Inc.
Phase 1 Unknown
NCT00882583 2019-01-09
Dasatinib
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT02350712 2018-09-11
Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer
Daiichi Sankyo
Phase 1 Completed
NCT02035527 2018-05-24
Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT00901537 2018-04-17
Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer
Loma Linda University
Phase 1 Terminated
NCT02277184 2017-11-13
Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma
University of Pittsburgh
Phase 1 Terminated
NCT02216617 2017-10-27
TAPIS
Groupe Oncologie Radiotherapie Tete et Cou
Phase 1 Completed
NCT00513383 2017-03-01
Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck
Massachusetts General Hospital
Phase 1 Completed
NCT00077051 2016-12-15
Cytochlor and Tetrahydrouridine as Radiosensitizers and Cisplatin Combined With Radiation Therapy in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity (Mouth) or Oropharynx (Throat)
University of Miami
Phase 1 Completed
NCT01283178 2016-10-31
Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC
Virginia Commonwealth University
Phase 1 Terminated
NCT01737008 2016-06-13
Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck
University Health Network, Toronto
Phase 1 Completed
NCT01360827 2014-06-17
EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck
Merck KGaA, Darmstadt, Germany
Phase 1 Terminated
NCT01728480 2013-12-11
Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy
Roswell Park Cancer Institute
Phase 1 Withdrawn
NCT00049166 2013-09-30
Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00006106 2013-07-10
ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT01058408 2013-02-22
RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT00033449 2013-01-25
Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00629226 2011-09-30
Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00010023 2011-04-05
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NYU Langone Health
Phase 1 Completed
NCT00402545 2009-11-02
C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Dana-Farber Cancer Institute
Phase 1 Completed